Clinical trials
for patients
Learn about available clinical trials
-
May 4, 2026MadridIn recruitmentEarly phase
-
May 4, 2026Pamplona/MadridIn recruitmentEarly phase
BAY 3547926/ 22262 First human trial to assess the safety and efficacy of BAY 3547926 in participants with advanced liver cancer.
The purpose of this trial is to determine whether the new drug BAY 3547926 can be safely administered to participants, to identify the optimal dose, and to investigate how this new drug works in participants with advanced hepatocellular carcinoma. -
April 27, 2026PamplonaIn recruitment
NT-PPR-EU002 A randomized, double-blind, parallel-group, multicenter Phase III clinical trial to investigate the safety and efficacy of NT201.
The aim of the study is to evaluate the safety and efficacy of NT 201 compared with placebo in adult participants with moderate to severe platysma prominence. -
April 22, 2026PamplonaIn recruitment
IVY-P3-24-021 A Phase III, open-label, randomized, two-arm clinical trial to compare the clinical efficacy and safety of niraparib with temozolomide in adult participants with newly diagnosed MGMT-unmethylated glioblastoma
This is a Phase III trial. This trial consists of: Phase 1, during which participants will receive either the study drug or the comparator drug, and all participants will also receive radiation therapy; and Phase 2, during which participants will continue to receive the same drug they received in Phase 1, without radiation therapy. -
April 22, 2026MadridIn recruitmentEarly phase
PHN-012-001 Clinical trial of PHN-012 in patients with advanced solid tumors.
The primary objective is to determine the MTD or MAD for intravenous PHN-012 monotherapy and to evaluate its safety and tolerability. -
April 21, 2026PamplonaIn recruitment
PF334 A global randomized trial comparing pulsed-field ablation of pulmonary veins using extra-PV sources with electrographic flow mapping versus posterior-wall pulmonary veins in patients with atrial fibrillation.
The purpose of this study is to gather more information about the safety and effectiveness of the FARAPULSE® pulsed-field ablation system, the OptiMap® catheter, and the OptiMap® system in the treatment of persistent atrial fibrillation. This study is intended for people who have symptoms, have not previously undergone ablation for atrial fibrillation, and have not responded to medication. -
April 21, 2026Pamplona/MadridIn recruitment
M25-586 A clinical trial to evaluate the efficacy and safety of etentamig and daratumumab (etentamig) compared with daratumumab, lenalidomide, and dexamethasone (DRd) in patients with newly diagnosed multiple myeloma who are not eligible for transplantation.
The objective of this study is to determine whether etentamig is safe and to identify the optimal dose of etentamig when combined with daratumumab in participants with newly diagnosed multiple myeloma (NDMM) who are not eligible for transplantation. -
April 20, 2026PamplonaIn recruitment
222714 Clinical trial to evaluate the efficacy and safety of depemokimab in adult participants with COPD and type 2 inflammation (ENDURA-1).
The aim is to determine whether depemokimab can improve COPD and make you feel better, and whether it is safe, well-tolerated, and effective. -
April 20, 2026PamplonaIn recruitment
CDX0159-16 A Phase 3, randomized, double-blind, placebo-controlled, multicenter, parallel-group clinical trial of barzolvolimab in participants with cold-induced urticaria and symptomatic dermographism (EMBARQ-COLDU and SD).
The aim of this research study is to evaluate the actual effectiveness of barzolvolimab and determine whether it helps people with cold-induced urticaria and symptomatic dermographism. -
April 20, 2026PamplonaIn recruitment
IDE196-010 A randomized, open-label Phase 3 clinical trial to evaluate darovasertib as a neoadjuvant treatment in patients with non-metastatic primary uveal melanoma (OptimUM-10)
The aim of the study is to determine whether the experimental drug called darovasertib (also known as IDE196) is safe and effective in people with a specific type of eye cancer called uveal melanoma (UM).